#868: Tim’s Founder Kitchen — From Brainstorm to The President’s Office in Two Months (Featuring Jake Becraft, Strand Therapeutics)

Genetic medicine stands at a revolutionary precipice, moving beyond liver-focused treatments toward programmable, systemic therapies. Strand Therapeutics CEO Jake Becraft details a platform-based approach that uses RNA to reprogram cells, enabling tumors to signal their own destruction to the immune system. This methodology, demonstrated by significant abscopal responses in visceral metastases, shifts the focus from incremental drug development to scalable infrastructure. Current regulatory frameworks, however, prioritize risk-averse, minor advancements over bold, first-principles innovation, often forcing clinical trials overseas to China or Australia. Streamlining the FDA’s initial first-in-human trial process through clinical trial notification systems would allow hospitals to accelerate testing, reduce costs, and maintain American competitiveness in the global biotechnology landscape. This transition from asset-based development to platform-centric infrastructure is essential for achieving hyper-personalized, curative treatments for complex diseases.